Nektar Therapeutics
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NKTR | ARTV | LKFT | BHVN | CRVS | AKTS | |
|---|---|---|---|---|---|---|
| Market cap | 1.36B | 330.99M | 1.94B | 1.78B | 845.42M | 964.44M |
| P/E (TTM) | — | — | 2.8 | — | — | — |
| Forward P/E | -3.9 | -2.6 | -24.9 | -6.3 | -9.4 | -8.1 |
| Price/book | 1.5 | 1.0 | 10.5 | 145.8 | 3.8 | 2.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −28.28% | +153.28% | −12.35% | −21.05% | +47.96% | −22.59% |
| Today | −3.23% | −2.45% | −0.54% | −2.24% | −4.47% | −4.46% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All NKTR news ›BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target
BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00. The price target implies an upside of 336.3% from the Oct 8 close of $40.80. Positive Initial Legal Outcomes: The favorable outcome of the…
Neumora Therapeutics (NASDAQ:NMRA) Cut to Strong Sell at Wall Street Zen
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report issued on Saturday, Wall Street Zen reports. Get Our Latest Stock…
NKTR Initiates Coverage On by Raymond James -- Rated Market Perform
On October 2, 2023, Nektar Therapeutics NKTR received an initiation of coverage from Raymond James, with analyst Thomas Deal designating the stock as Market Perform. This signifies a neutral outlook without a specified price target. The GF…
Reviewing Verastem (NASDAQ:VSTM) and Nektar Therapeutics (NASDAQ:NKTR)
Posted by Michael Walen on Oct 4th, 2026 Verastem (NASDAQ:VSTM – Get Free Report) and Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two…
Nektar Therapeutics (NKTR) Shareholder/Analyst Call - Slideshow
(NASDAQ:NKTR) 2026-10-03 Seeking Alpha The following slide deck was published by Nektar Therapeutics in conjunction with this event.
Nektar Therapeutics downgraded to Hold over saf...
Nektar Therapeutics has been downgraded from Strong Buy to Hold due to safety concerns related to its drug REZPEG, despite positive efficacy results from the Phase 2b REZOLVE-AA study. The study showed 63% durability off-treatment but…
Nektar Therapeutics (NASDAQ:NKTR) Stock Price Down 5.7% – Should You Sell?
Posted by Mitch Edgeman on Oct 2nd, 2026 Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) traded down 5.7% during mid-day trading on Friday. The company traded as low as $44.76 and last traded at $44.32. 1,013,856 shares…
Nektar Therapeutics (NKTR) Shares Drop After Rezpegaldesleukin T
Overall, NKTR’s fundamental profile reflects the challenges typical of clinical-stage biotechs: promising pipeline assets but substantial financial risks and no current profitability. Investors should weigh the company’s momentum and…
Nektar stock posts mid-stage data for hair loss drug (NKTR)
Nektar Therapeutics (NKTR) stock dips as the company posts new mid-stage trial data for its hair loss candidate, rezpegaldesleukin. Read more here.
NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge
Shares of Nektar Therapeutics (NKTR) fell sharply by 21% on Thursday even as the company reported that its experimental skin drug, rezpegaldesleukin, kept working after treatment stopped, though the new response rates were modest and drawn…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
tradingview.com4
-
seekingalpha.com3
-
gurufocus.com2
-
themarketsdaily.com2
-
genengnews.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 16 articles, not a forecast.